Speciality Medicines
Speciality Medicines (SPML) share price was ₹141.10 at the 27 Oct 2026 close; sector Healthcare. In the Mar 2026 quarter, revenue was ₹45 Cr, against ₹31 Cr a year earlier and net profit was ₹8 Cr, against ₹3 Cr a year earlier (compared with Mar 2025). Promoters held 43.43% of Speciality Medicines in Mar 2026.
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| ₹1,767.20 | 35.06 | 4,24,010 Cr | 5.07 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,655.00 | 87.63 | 2,56,310 Cr | 15.29 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,604.50 | 72.28 | 1,75,140 Cr | 9.53 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,187.30 | 108.07 | 1,18,182 Cr | 22.30 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,181.00 | 26.28 | 1,17,805 Cr | 4.35 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,338.40 | 34.66 | 1,11,714 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,362.50 | 32.64 | 1,10,071 Cr | 3.11 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Speciality Medicines (this company) | — | — | — | — | — | — | — | — | — |
| Median 8 companies | ₹1,767.20 | 35.06 | 1,18,182 Cr | 5.07 | 0.61% | 13.79% | 17.94% | 28,515 Cr | 3,184 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100. How it works →
No Tapetide Score has been computed for this stock yet.
Key Insights
Strengths
2- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 27.5%
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Tax rate seems low
Technical Indicators
Oscillators
Bullish
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
Quarterly Results
| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 31 | 45 |
| Expenses | 26 | 36 |
| Operating Profit | 4 | 8 |
| OPM % | 14% | 19% |
| Other Income | 0 | 1 |
| Interest | 0 | 1 |
| Depreciation | 0 | 0 |
| PBT | 4 | 8 |
| Tax % | 36% | -1% |
| Net Profit | 3 | 8 |
| EPS (₹) | 4.16 | 9.31 |
Profit & Loss
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 40 | 23 | 28 | 58 | 75 |
| Expenses | 38 | 20 | 22 | 49 | 62 |
| Operating Profit | 2 | 4 | 5 | 9 | 14 |
| OPM % | 6% | 15% | 19% | 16% | 18% |
| Other Income | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 |
| PBT | 2 | 3 | 5 | 9 | 13 |
| Tax % | 31% | 43% | 36% | 17% | 0% |
| Net Profit | 1 | 2 | 3 | 7 | 13 |
| EPS (₹) | 70.48 | 4.42 | 5.73 | 11.19 | 14.83 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity Capital | 0.21 | 4 | 5 | 6 | 9 |
| Reserves | 2 | 2 | 10 | 24 | 62 |
| Borrowings | 1 | 4 | 3 | 5 | 7 |
| Other Liabilities | 3 | 4 | 5 | 4 | 17 |
| Total Liabilities | 6 | 13 | 23 | 40 | 95 |
| Fixed Assets | 2 | 2 | 1 | 2 | 2 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 4 | 11 | 21 | 38 | 93 |
| Total Assets | 6 | 13 | 23 | 40 | 95 |
Cash Flow
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating | 1 | -4 | -5 | -6 | -1 |
| Investing | -2 | 0 | 0 | -1 | -3 |
| Financing | 2 | 4 | 5 | 8 | 28 |
| Net Cash Flow | 0 | 0 | 0 | 1 | 24 |
| Free Cash Flow | -1 | -4 | -5 | -7 | -1 |
| CFO/OP | 36 | -101 | -66 | -54 | -9 |
Ratios
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor Days | 23 | 87 | 142 | 60 | 128 |
| Inventory Days | 5 | 103 | 161 | 150 | 191 |
| Days Payable | 12 | 40 | 48 | 8 | 80 |
| Cash Conversion Cycle | 16 | 149 | 255 | 202 | 239 |
| Working Capital Days | -3 | 76 | 185 | 181 | 221 |
| ROCE % | — | 52% | 38% | 34% | 25% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Speciality Medicines insights
48 extracted metrics + investor summaries across FY22–FY26.
Documents
Frequently Asked Questions about Speciality Medicines
What does Speciality Medicines Ltd do?
Where is Speciality Medicines Ltd (SPML) listed?
Which sector does Speciality Medicines Ltd belong to?
Company Information
Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544738.md for Speciality Medicines Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.